{"id":295735,"date":"2019-10-02T22:30:26","date_gmt":"2019-10-03T05:30:26","guid":{"rendered":"https:\/\/nai500.com\/blog\/2019\/10\/iaso-and-innovent-approved-to-start-trial\/"},"modified":"2019-10-03T00:27:59","modified_gmt":"2019-10-03T07:27:59","slug":"%e9%a9%af%e9%b9%bf%e5%8c%bb%e7%96%97%e5%92%8c%e4%bf%a1%e8%be%be%e7%94%9f%e7%89%a9%e8%8e%b7%e5%87%86%e5%90%af%e5%8a%a8car-t","status":"publish","type":"post","link":"https:\/\/nai500.com\/zh-hans\/blog\/2019\/10\/%e9%a9%af%e9%b9%bf%e5%8c%bb%e7%96%97%e5%92%8c%e4%bf%a1%e8%be%be%e7%94%9f%e7%89%a9%e8%8e%b7%e5%87%86%e5%90%af%e5%8a%a8car-t\/","title":{"rendered":"\u9a6f\u9e7f\u533b\u7597\u548c\u4fe1\u8fbe\u751f\u7269\u83b7\u51c6\u542f\u52a8CAR-T\u514d\u75ab\u7597\u6cd5\u7684\u8bd5\u9a8c"},"content":{"rendered":"<p>\u5357\u4eac\u9a6f\u9e7f\u533b\u7597\u6280\u672f\u6709\u9650\u516c\u53f8\u53ca\u5176\u5408\u4f5c\u4f19\u4f34\u82cf\u5dde\u4fe1\u8fbe\u751f\u7269\u5ba3\u5e03\uff0c\u4ed6\u4eec\u5171\u540c\u5f00\u53d1\u7684CAR-T\u7597\u6cd5\u88ab\u6279\u51c6\u5728\u4e2d\u56fd\u5f00\u59cb\u5bf9\u590d\u53d1\/\u96be\u6cbb\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u8fdb\u884cIb \/ II\u671f\u8bd5\u9a8c\u3002\u9a6f\u9e7f\u533b\u7597\u8868\u793a\uff0cCT103A\u662f\u4e3a\u5728CAR-T\u6cbb\u7597\u540e\u590d\u53d1\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u8bbe\u8ba1\u7684\u3002\u9a6f\u9e7f\u533b\u7597\u8fd8\u8868\u793a\uff0c\u5728\u4e00\u9879\u4e2d\u56fdIIT\u7814\u7a76\u4e2d\uff0c\u6bcf8\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\u4e2d\u67097\u4f8b\u5b9e\u73b0\u4e86\u5f88\u597d\u7684\u5c40\u90e8\u53cd\u5e94\u6216\u66f4\u597d\u7597\u6548\u3002<\/p>\n<p>\u82f1\u6587\u6765\u6e90\uff1aChina Biotoday<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IASO Biotherapeutics of Nanjing and its partner, Suzhou Innovent Biologics, announced that their jointly developed CAR-T therapy was approved to start a Phase Ib\/II trial in China in patients with relapsed\/refractory multiple myeloma. IASO said CT103A was designed for rr\/mm patients who have relapsed after CAR-T treatment. Because repeat CAR-T rounds are not effective, CT103A was developed using a lentiviral vector containing a CAR structure. IASO said 7 out of 8 evaluable patients in a China IIT study achieved very good partial response or better.<\/p>\n","protected":false},"author":9,"featured_media":295732,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[427],"tags":[459],"class_list":["post-295735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-news-zh-hans","tag-459","sectors-life-science-zh-hans","locations-china-zh-hans"],"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts\/295735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=295735"}],"version-history":[{"count":0,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts\/295735\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/media\/295732"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=295735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=295735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=295735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}